Aurora Financial Journal

Takeda Pharmaceutical Company (4502.T)

Tokyo Stock Exchange · Pharmaceutical industry · Financial statements, TTM figures and earnings dates

In fiscal year 2025 (ended March 31, 2025), Takeda Pharmaceutical Company reported revenue of ¥4.58T and net income of ¥107.93B. Annual financial statements are available for fiscal years 2017 to 2025, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

JPYFY2025
2025-03-31		FY2024
2024-03-31		FY2023
2023-03-31		FY2022
2022-03-31		FY2021
2021-03-31
Income statement
Revenue¥4.58T¥4.26T¥4.03T¥3.57T¥3.20T
Gross profit¥3.00T¥2.84T¥2.78T¥2.46T¥2.20T
Operating income¥342.59B¥214.07B¥490.50B¥460.84B¥509.27B
Net income¥107.93B¥144.07B¥317.02B¥230.06B¥376.00B
Diluted EPS¥67.23¥91.16¥201.94¥145.87¥238.96
Cash flow
Operating cash flow¥1.06T¥716.34B¥977.16B¥1.12T¥1.01T
Capital expenditure¥200.79B¥175.42B¥140.66B¥123.25B¥111.21B
Free cash flow¥856.39B¥540.92B¥836.50B¥999.85B¥899.73B
Balance sheet
Cash and equivalents¥385.11B¥457.80B¥533.53B¥849.70B¥966.22B
Total assets¥14.25T¥15.11T¥13.96T¥13.18T¥12.91T
Total liabilities¥7.31T¥7.83T¥7.60T¥7.49T¥7.74T
Total debt¥4.52T¥4.84T¥4.38T¥4.35T¥4.64T
Shareholders' equity¥6.94T¥7.27T¥6.35T¥5.68T¥5.17T

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in JPY as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full 4502.T page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open 4502.T financials →